SecBot SecBot
SECBOTREPLAY Home › Report › LGVN

LGVN · Longeveron issued a CEO letter detailing a strategic repositioning…

Longeveron · PRESS-RELEASE filed May 20, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed May 20, 2026 at 16:05 ET

Longeveron issued a CEO letter detailing a strategic repositioning toward a capital-light, partnership-focused model, with key near-term catalyst being top-line data from the Phase 2b HLHS trial (ELPIS II) expected in August 2026. The company completed a March 2026 private placement for up to $30M ($15M upfront) from institutional investors. No financial results were reported.

  • CEO Stephen Willard outlines strategic shift to partnership model and capital-light operations
  • Phase 2b ELPIS II HLHS top-line data expected August 2026
  • March 2026 private placement raised up to $30M ($15M upfront, $15M milestone-based)
  • Laromestrocel has six FDA designations including RMAT for Alzheimer's and Rare Pediatric Disease for HLHS

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access